# The First Affiliated Hospital with Nanjing Medical University: Phase 2 study in PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma (40 participants)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Sponsor type | Academic and hospital |
| Study | Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma |
| NCT ID | NCT07888621 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | PCNSL (Primary CNS Lymphoma); Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma (SCNSL) |
| Intervention types | drug, radiation |
| Target enrollment | 40 |
| Site countries | China |
| Posted | 2026-10-22 |
| Planned start | 2026-11 |
| Event | Newly registered study |
| Event date | 2026-10-22 |

## Why this score
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07888621). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.